Enterprise Financial Services Corp (EFSC)’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-10
| Closed | -$1K | – | 1368 |
|
|
2020
Q4 | $1K | Buy |
+10
| New | +$1K | ﹤0.01% | 1169 |
|
|
2020
Q2 | – | Sell |
-18
| Closed | -$2K | – | 1278 |
|
|
2020
Q1 | $2K | Buy |
+18
| New | +$2K | ﹤0.01% | 981 |
|
|
2019
Q3 | – | Sell |
-25
| Closed | -$2K | – | 1132 |
|
|
2019
Q2 | $2K | Sell |
25
-19
| -43% | -$1.52K | ﹤0.01% | 1011 |
|
|
2019
Q1 | $4K | Buy |
44
+19
| +76% | +$1.73K | ﹤0.01% | 936 |
|
|
2018
Q4 | $2K | Sell |
25
-38
| -60% | -$3.04K | ﹤0.01% | 797 |
|
|
2018
Q3 | $6K | Buy |
63
+38
| +152% | +$3.62K | ﹤0.01% | 688 |
|
|
2018
Q2 | $2K | Sell |
25
-32
| -56% | -$2.56K | ﹤0.01% | 844 |
|
|
2018
Q1 | $5K | Hold |
57
| – | – | ﹤0.01% | 712 |
|
|
2017
Q4 | $5K | Hold |
57
| – | – | ﹤0.01% | 690 |
|
|
2017
Q3 | $5K | Sell |
57
-40
| -41% | -$3.51K | ﹤0.01% | 695 |
|
|
2017
Q2 | $9K | Sell |
97
-140
| -59% | -$13K | ﹤0.01% | 594 |
|
|
2017
Q1 | $21K | Hold |
237
| – | – | 0.01% | 445 |
|
|
2016
Q4 | $20K | Buy |
237
+57
| +32% | +$4.81K | 0.01% | 441 |
|
|
2016
Q3 | $17K | Hold |
180
| – | – | 0.01% | 447 |
|
|
2016
Q2 | $14K | Hold |
180
| – | – | 0.01% | 471 |
|
|
2016
Q1 | $15K | Buy |
180
+158
| +718% | +$13.2K | 0.01% | 451 |
|
|
2015
Q4 | $2K | Hold |
22
| – | – | ﹤0.01% | 905 |
|
|
2015
Q3 | $2K | Hold |
22
| – | – | ﹤0.01% | 868 |
|
|
2015
Q2 | $3K | Sell |
22
-74
| -77% | -$10.1K | ﹤0.01% | 818 |
|
|
2015
Q1 | $12K | Hold |
96
| – | – | 0.01% | 551 |
|
|
2014
Q4 | $9K | Hold |
96
| – | – | 0.01% | 633 |
|
|
2014
Q3 | $7K | Sell |
96
-17
| -15% | -$1.24K | ﹤0.01% | 678 |
|
|
2014
Q2 | $7K | Buy |
113
+1
| +0.9% | +$62 | ﹤0.01% | 709 |
|
|
2014
Q1 | $8K | Hold |
112
| – | – | ﹤0.01% | 675 |
|
|
2013
Q4 | $8K | Hold |
112
| – | – | ﹤0.01% | 634 |
|
|
2013
Q3 | $8K | Buy |
112
+13
| +13% | +$929 | 0.01% | 607 |
|
|
2013
Q2 | $6K | Buy |
+99
| New | +$6K | ﹤0.01% | 572 |
|